tyrosyl-isoleucyl-glycyl-seryl-arginine has been researched along with Leukemia, Pre-B-Cell in 1 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 1 (100.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 0 (0.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Hara, T; Ishii, E; Kinukawa, N; Matsuzaki, A; Miyazaki, S; Mohri, S; Nomizu, M; Oshima, K; Yamada, Y; Yoshida, N | 1 |
1 other study(ies) available for tyrosyl-isoleucyl-glycyl-seryl-arginine and Leukemia, Pre-B-Cell
Article | Year |
---|---|
The laminin-derived peptide YIGSR (Tyr-Ile-Gly-Ser-Arg) inhibits human pre-B leukaemic cell growth and dissemination to organs in SCID mice.
Topics: Actins; Animals; Antigens, CD19; Antineoplastic Agents; Cell Division; Humans; Laminin; Mice; Mice, SCID; Neoplasm Invasiveness; Neoplasm Metastasis; Neprilysin; Oligopeptides; Precursor B-Cell Lymphoblastic Leukemia-Lymphoma; Reverse Transcriptase Polymerase Chain Reaction; Transplantation, Heterologous; Tumor Cells, Cultured | 1999 |